Broad Kinase Inhibition Mitigates Early Neuronal Dysfunction in Tauopathy.

ABSTRACT: Tauopathies are a group of more than twenty known disorders that involve progressive neurodegeneration, cognitive decline and pathological tau accumulation. Current therapeutic strategies provide only limited, late-stage symptomatic treatment. This is partly due to lack of understanding of the molecular mechanisms linking tau and cellular dysfunction, especially during the early stages of disease progression. In this study, we treated early stage tau transgenic mice with a multi-target kinase inhibitor to identify novel substrates that contribute to cognitive impairment and exhibit therapeutic potential. Drug treatment significantly ameliorated brain atrophy and cognitive function as determined by behavioral testing and a sensitive imaging technique called manganese-enhanced magnetic reson

SUBMITTER: Koren SA 

PROVIDER: S-EPMC7865413 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature